

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (original) A crystalline tolterodine tartrate form I, characterized by an x-ray powder diffraction spectrum having peaks expressed as  $2\theta$  at about 11.9, 13.6, 14.2, 15.9, 16.9, 18.4, 18.8, 20.4, 22.0, 23.9, 25.4, 26.3 and 29.8 degrees.
2. (currently amended) A The crystalline tolterodine tartrate form I as defined in claim 1, further characterized by an x-ray powder diffraction spectrum as in figure 1.
3. (currently amended) A The process for preparation of tolterodine tartrate form I as defined in claim 1, which comprises the steps of:
  - a) dissolving tolterodine free base in a suitable solvent;
  - b) adding tartaric acid; and
  - c) isolating tolterodine tartrate form I;wherein the suitable solvent is selected from the group consisting of ethanol, methylene dichloride, chloroform, acetone, acetonitrile and 1,4-dioxane.
4. (currently amended) A The process according to claim 3, wherein the suitable solvent is ethanol.
5. (currently amended) A The process according to claim 3, wherein the suitable solvent is acetone.
6. (original) A crystalline tolterodine tartrate form II, characterized by an x-ray powder diffraction spectrum having peaks expressed as  $2\theta$  at about 8.7, 9.0, 9.6, 10.1, 10.4, 11.9, 14.0, 15.7, 16.9, 17.6, 17.9, 18.4, 18.7, 20.0, 20.5, 22.1, 24.5, 29.1 and 35.9 degrees.
7. (currently amended) A The crystalline tolterodine tartrate form II as defined in claim 6, further characterized by an x-ray powder diffraction spectrum as in figure 2.
8. (currently amended) A The process for preparation of tolterodine tartrate form II as defined in claim 6, which comprises the steps of:

- a) dissolving tolterodine free base in ethyl acetate;
  - b) adding tartaric acid; and
  - c) isolating tolterodine tartrate form II.
9. (original) A crystalline tolterodine tartrate form III, characterized by an x-ray powder diffraction spectrum having peaks expressed as  $2\theta$  at about 9.1, 9.7, 10.6, 11.7, 11.9, 12.7, 14.3, 15.7, 17.9, 18.5, 18.8, 19.1, 20.1, 20.4, 22.1, 22.5, 25.1, 32.8 and 35.5 degrees.
10. (currently amended) A The crystalline tolterodine tartrate form III as defined in claim 9, further characterized by an x-ray powder diffraction spectrum as in figure 3.
11. (currently amended) A The process for preparation of tolterodine tartrate form III as defined in claim 9, which comprises the steps of:
- a) dissolving tolterodine free base in methyl tert-butyl ether;
  - b) adding tartaric acid; and
  - c) isolating tolterodine tartrate form III.
12. (original) A crystalline tolterodine tartrate form IV, characterized by an x-ray powder diffraction spectrum having peaks expressed as  $2\theta$  at about 7.8, 9.8, 15.2, 17.2, 17.7, 18.4, 18.9, 20.3 and 25.9 degrees.
13. (currently amended) A The crystalline tolterodine tartrate form IV as defined in claim 12, further characterized by an x-ray powder diffraction spectrum as in figure 4.
14. (currently amended) A The process for preparation of tolterodine tartrate form IV as defined in claim 12, which comprises the steps of:
- a) mixing tolterodine tartrate, an alcohol and water; and
  - b) removing the solvents from the solution formed in step (a) by freeze drying;
- wherein the alcohol is selected from the group consisting of methanol, ethanol, isopropyl alcohol and n-butanol.
15. (currently amended) A The process according to claim 14, wherein the suitable alcohol is methanol.
16. (currently amended) A The process according to claim 14, wherein the suitable alcohol is ethanol.

17. (original) Amorphous tolterodine tartrate characterized by an x-ray powder diffraction spectrum as in figure 5.
18. (currently amended) A The process for preparation of amorphous tolterodine tartrate as defined in claim 17, which comprises the steps of:
- a) mixing tolterodine tartrate, an alcohol and water; and
  - b) removing the solvents from the solution formed in step (a) by vacuum drying or by spray drying;
- wherein the alcohol is selected from the group consisting of methanol, ethanol, isopropyl alcohol and n-butanol.
19. (currently amended) A The process according to claim 18, wherein the suitable alcohol is methanol.
20. (currently amended) A The process according to claim 18, wherein the suitable alcohol is ethanol.
21. (currently amended) A The process according to claim 18, wherein the solvents are removed by vacuum drying.
22. (currently amended) A The process according to claim 18, wherein the solvents are removed by spray drying.
23. (original) A pharmaceutical composition comprising a polymorphic form of tolterodine tartrate and a pharmaceutically acceptable carrier or diluent.
24. (currently amended) A The pharmaceutical composition as defined in claim 24, wherein the polymorphic form is tolterodine tartrate form I of claim 1.
25. (currently amended) A The pharmaceutical composition as defined in claim 24, wherein the polymorphic form is tolterodine tartrate form II of claim 6.
26. (currently amended) A The pharmaceutical composition as defined in claim 24, wherein the polymorphic form is tolterodine tartrate form III of claim 9.
27. (currently amended) A The pharmaceutical composition as defined in claim 24, wherein the polymorphic form is tolterodine tartrate form IV of claim 12.

National Stage of PCT/IN03/00149  
Attorney Docket No. H1089/20020  
Preliminary Amendment Dated October 6, 2004

28. (currently amended) A The pharmaceutical composition as defined in claim 24, wherein the polymorphic form is amorphous tolterodine tartrate of claim 17.